JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

DOI PDF 被引用文献17件
  • Elisa Rumi
    Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Daniela Pietra
    Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Virginia Ferretti
    Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Thorsten Klampfl
    Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
  • Ashot S. Harutyunyan
    Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
  • Jelena D. Milosevic
    Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
  • Nicole C. C. Them
    Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
  • Tiina Berg
    Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
  • Chiara Elena
    Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Ilaria C. Casetti
    Department of Molecular Medicine, University of Pavia, Pavia, Italy;
  • Chiara Milanesi
    Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Emanuela Sant’Antonio
    Department of Molecular Medicine, University of Pavia, Pavia, Italy;
  • Marta Bellini
    Department of Molecular Medicine, University of Pavia, Pavia, Italy;
  • Elena Fugazza
    Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Maria C. Renna
    Department of Molecular Medicine, University of Pavia, Pavia, Italy;
  • Emanuela Boveri
    Anatomic Pathology Section, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy; and
  • Cesare Astori
    Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Cristiana Pascutto
    Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Robert Kralovics
    Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
  • Mario Cazzola
    Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;

書誌事項

公開日
2014-03-06
DOI
  • 10.1182/blood-2013-11-539098
公開者
American Society of Hematology

この論文をさがす

説明

<jats:title>Key Points</jats:title> <jats:p>JAK2 (V617F)-mutated essential thrombocythemia and polycythemia vera are different phenotypes in the evolution of a single neoplasm. CALR-mutated essential thrombocythemia is a distinct disease entity not only at the molecular level, but also with respect to clinical outcomes.</jats:p>

収録刊行物

  • Blood

    Blood 123 (10), 1544-1551, 2014-03-06

    American Society of Hematology

被引用文献 (17)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ